Symbols

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

MNOV

MediciNova·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MNOV

Medicinova, Inc.

A biopharmaceutical company developing products primarily focused on neurology, respiratory

Industry

Chemical and pharmaceutical

Established Date

09/26/2000

Listing Date

12/07/2006

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.medicinova.com

Security Type

Common stock

Office address

4275 Executive Square Suite 300 La Jolla California 92037

Business

Develops therapeutics for neurological and fibrotic disorders.

Introduction

MediciNova, Inc., was originally incorporated in Delaware on September 26, 2000. The company is a biopharmaceutical company focused on developing novel therapies for the treatment of serious diseases with unmet medical needs, with a commercial focus on the US market. The company's current strategy is to concentrate R&D resources to advance the following two core drug candidates: MN-166 (ibudilast): for the treatment of neurological and other related diseases, including progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (such as methamphetamine dependence), And prevention of acute respiratory distress syndrome (ARDS); MN-001 (tipelukast): for the treatment of fibrosis and other metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia.

Company Financials

EPS

MNOV has released its 2026 Q1 earnings. EPS was reported at -0.05, versus the expected -0.06, beating expectations. The chart below visualizes how MNOV has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MNOV has released its 2026 Q2 earnings report, with revenue of 458.44K, reflecting a YoY change of 240.60%, and net profit of -2.31M, showing a YoY change of 29.47%. The Sankey diagram below clearly presents MNOV's revenue sources and cost distribution.